Pod Digital Media Celebrates Seven Years of Connecting Brands Authentically to Growth Audiences
Over the past year, PDM has significantly expanded its reach, growing 232 percent. This growth includes welcoming new shows–Money Talks with Terrence J and More to the Story with Rocsi Diaz–and new brand partners like Merck, Fiji and more.
Share
Over the past year, PDM has significantly expanded its reach, growing 232 percent. This growth includes welcoming new shows– Money Talks with Terrence J and More to the Story with Rocsi Diaz– and new brand partners like Merck, Fiji and more. PDM has also continued its strong partnerships with leading brands such as McDonald's, Coca-Cola and Walmart, further solidifying PDM's position as a leader in the growth audience advertising business.
'Podcast advertising has evolved into an essential omnichannel for brands seeking authentic, long-lasting cultural connections where nuance is necessary,' says Gary Coichy, chief executive officer of Pod Digital Media. 'PDM has become a vital cultural hub. Our new Pod House division, offering custom podcast content and in-person engagements, as well as unique experiential events, truly positions brands for community and commerce. Our work has created stronger customer relationships, enhanced brand reputation, and sustainable business growth for our partners.'
PDM's holistic approach to advertising goes beyond traditional ad spots, offering 360-degree campaigns that integrate custom content, influential voices, and in-real-life experiences. This comprehensive strategy ensures brands can forge deeper, more meaningful connections with valuable audiences, to drive engagement and foster brand loyalty.
Building on its award-winning work recognized by the Association of National Advertisers, PDM aims to shape the future of growth audiences through podcasts, influencers, live events, and activations.
About Pod Digital Media
As a certified minority-owned small business based in New York City, Pod Digital Media is the first podcast agency network that exclusively caters to podcasters with growth audiences and connects them to blue-chip advertisers for long-term, seasonal, and special investments. With more than 400 podcasts reaching primarily Black and Hispanic American audience segments, the agency places ads on their shows and delivers tangible results to advertisers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics
We recently published . OPKO Health, Inc. (NASDAQ:OPK) is one of the best healthcare stocks. OPKO Health, Inc. (NASDAQ:OPK) is a diversified healthcare company with operations in diagnostics, pharmaceuticals, and innovative therapies, anchored by BioReference Laboratories and an expanding drug development pipeline. The company is advancing programs in immunology, endocrinology, oncology, and metabolic disorders through both internal research and strategic collaborations. In 2025, OPKO Health, Inc. (NASDAQ:OPK) made notable progress across multiple fronts. In partnership with Merck, it is advancing a Phase 1 trial for an experimental Epstein-Barr virus (EBV) vaccine, which could move to Phase 2 pending trial results. Its metabolic disease pipeline includes OPK-88006, an investigational oral GLP-1/glucagon dual agonist for obesity and metabolic-associated steatohepatitis (MASH). Data presented at ENDO 2025 demonstrated strong bioavailability and efficacy, with both oral and weekly injectable formats in development. The company is also working with Entera Bio on an oral GLP-2 agonist for short bowel syndrome, with promising PK/PD data set for presentation at the 2025 ESPEN Congress. In oncology, the business's subsidiary ModeX is developing multispecific antibody therapeutics, with four clinical candidates, including lymphoma and leukemia treatments, targeting a range of solid tumors and blood cancers, and human trials expected to begin in early 2026. Photo by National Cancer Institute on Unsplash On the diagnostics front, the FDA approved a key update to OPKO's 4KScore Test, allowing use without digital rectal examination data, broadening its role in primary care for prostate cancer risk assessment. Additionally, the planned sale of certain BioReference oncology and clinical testing assets to Labcorp, expected to close in late 2025, will allow OPKO Health, Inc. (NASDAQ:OPK) to sharpen its focus on core diagnostics and pharmaceuticals while improving operational efficiency. While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Colin Kaepernick docuseries produced by Spike Lee no longer moving forward at ESPN amid 'creative differences'
An ESPN docuseries on quarterback Colin Kaepernick that was being produced by acclaimed director Spike Lee and Jemele Hill is no longer moving forward. The six-time Academy Award nominee revealed to Reuters during a red carpet entrance at a fundraising dinner for the Harold and Carole Pump Foundation dinner on Friday that the multi-part documentary will not be released. "I can't. I signed a nondisclosure," he said. "I can't talk about it." Asked why the series — tentatively titled "Da Saga of Colin Kaepernick" — won't be seen, Lee cited a nondisclosure agreement in talking about the development. "I can't. I signed a nondisclosure," he added. "I can't talk about it." ESPN issued a statement to Reuters on Saturday in response to an inquiry about the docuseries' status. "ESPN, Colin Kaepernick and Spike Lee have collectively decided to no longer proceed with this project as a result of certain creative differences," the statement said. "Despite not reaching finality, we appreciate all the hard work and collaboration that went into this film." Kaepernick played in the NFL with the San Francisco 49ers for six seasons from 2011-16. He quarterbacked the 49ers to the 2013 NFC championship game, where they lost to the Seattle Seahawks. However, he is most known for protesting the U.S. national anthem before games by taking a knee as a gesture to protest systemic racism in the culture and police brutality. That made him a nationally controversial figure, drawing criticism from many including President Donald Trump, and presumably led to no NFL teams signing him after he became a free agent. He never played in the NFL again after the 2016 season. Last September, Puck's Matthew Belloni reported that creative differences between Kaepernick and Lee stalled the docuseries' development. Kaepernick preferred for the series to focus more on his career and personal experience. Yet Lee wanted the scope of the project to cover wider cultural issues, including the history of Black athletes in professional sports, social justice and police brutality. Though the series was reportedly completed, Kaepernick held ultimate approval over the project and wanted material added to Lee's final cut. The project stalling over creative differences between Kaepernick and Lee was confirmed to The Athletic, though specifics beyond what Belloni originally reported were not provided. Yet as Richard Deitsch and Andrew Marchand point out, ESPN's relationship with the NFL is different now than when the project was initially being developed in 2022. In an agreement worth billions of dollars, ESPN will acquire NFL RedZone and other NFL Media properies with the NFL taking a 10% equity stake in the network. A docuseries that potentially casts the NFL, commissioner Roger Goodell and the league's 32 teams in a bad light likely wouldn't be viewed favorably under those circumstances. Kaepernick filed a collusion grievance against NFL team owners with teammate Eric Reid. That lawsuit was eventually settled in 2019. The Kaepernick docuseries is reportedly finished or close enough to where it could air on another network or streaming platform. According to Belloni's report, Kaepernick and Lee largely worked out their differences. Yet based on the finality of Lee's remarks to Reuters, it appears that the project will not be shopped around to other outlets.
Yahoo
5 hours ago
- Yahoo
This Ultra-High-Dividend Yield Stock Is Up 25% So Far This Year
Key Points Tobacco giant Altria Group has outperformed the broad market in 2025. Price hikes continue to stabilize the company's cash flows. An ongoing share buyback program will support dividend growth in the years to come. 10 stocks we like better than Altria Group › The stock market is soaring. On a total return basis, the S&P 500 is up 10% year to date, 57% in the past three years, and over 100% in the last five years. It may surprise you to learn, however, that leading tobacco company Altria Group (NYSE: MO) has been outperforming the broad market, despite the long-term decline of smoking in the U.S. That's due in large part to the stock's juicy dividend, which yields 6.2% as of this writing. Altria reported its second-quarter earnings on July 30. Results showed continued progress in its strategy to optimize cash flows over the long term. The stock has steadily climbed following the report and is now up over 25% so far this year. The recent gains mean Altria is trading at levels not seen since 2018. Should you buy this dividend stock as it approaches its previous all-time high? Let's look at the numbers and find out. Price increases and cash flow Altria holds the rights to the famed Marlboro cigarette brand in the U.S. It has employed a consistent strategy for decades to optimize cash flows from the shrinking cigarette category. In the face of consistent volume declines and waning demand from consumers in the country, Altria regularly raises prices on cigarettes, counteracting the volume declines. Q2 numbers illustrate this dynamic. Altria's cigarette volume declined 10.2% year over year, while revenue net of excise taxes was flat year over year. Operating income still grew 4.4% for the smokeables category, which was helped by the cigars segment where the Black & Mild brand posted volume increases. These price hikes are how Altria consistently increases its free cash flow. In the last 12 months, the company generated $8.7 billion in free cash flow, which is close to a record high (excluding a 2020 period of irregular inventory and working capital dynamics). As price hikes continue, Altria Group should see stable cash flows from the cigarette and smokeables division as a whole. Can nicotine pouches save the day? Like the other nicotine giants, Altria Group has made investments into alternative nicotine categories such as vaping and nicotine pouches. Some of these have been successful, while others were wild failures, such as its investment in Juul vaping before the brand's collapse. Today, the company is showing growth with its On! nicotine pouch brand and NJOY vaping division. On! volume grew 26.5% year over year last quarter to 52.1 million cans sold. However, this didn't even fully counteract the volume declines from chewing tobacco brands such as Copenhagen as overall oral nicotine volumes were down 1.0%. Oral nicotine revenue net of excise taxes was $728 million last quarter, or just 16% of the size of Altria's smokeables division. Something that could affect Altria's growth going forward is a government crackdown on illicit vaping devices, which have flooded the U.S. market. These devices are technically illegal, but they're wildly popular and eat into sales for Altria's nicotine pouches, vaping products, and even cigarettes. A stricter regulatory environment could be a boon for volume growth across the business. The math behind the dividend growth At the end of the day, cash flows from legacy smokeable products will continue to drive the business for years to come. With these cash flows, management returns capital to shareholders through share repurchases and dividends. Altria's free cash flow per share was $5.16 over the last 12 months. This gives the company plenty of coverage for its $4.08 dividend per share payout to shareholders. With the excess cash accumulating on the balance sheet, management is retiring shares outstanding through stock buybacks, which will further boost free cash flow per share and help with future dividend growth. Over the last 10 years, Altria's shares outstanding have fallen 14%. Price increases, margin expansion, and a little help from newer categories like nicotine pouches can help Altria maintain its overall free cash flow levels, allowing Altria to sustain its streak of annual dividend increases. With a 6.2% yield, Altria Group still looks like a good dividend stock to buy today, even after its strong gains year to date. Should you invest $1,000 in Altria Group right now? Before you buy stock in Altria Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Altria Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This Ultra-High-Dividend Yield Stock Is Up 25% So Far This Year was originally published by The Motley Fool Sign in to access your portfolio
